NCT04443062View on ClinicalTrials.gov

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

March 1, 2025

Study Completion Date

January 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

177Lu-PSMA-617

PSMA radioligand therapy

Trial Locations (4)

Unknown

German Oncology Center, Limassol

Amsterdam UMC, Amsterdam

University Medical Center Groningen, Groningen

Radboud University, Nijmegen

Sponsors
All Listed Sponsors
collaborator

Prostaatkankerstichting

UNKNOWN

collaborator

Advanced Accelerator Applications

INDUSTRY

lead

Radboud University Medical Center

OTHER